Perficient: Drug Development

JANUARY 25, 2024

To recap: Part 1 of the series focused on providers This part, Part 2, focuses on payers (insurance companies) Part 3 (by Marlana Voerster ) will focus on medical-device organizations First off: the bad news in trust for payers Gallup’s polling data among U.S.

Nurses 52

Nurses Health Insurance Companies Pharmaceutical Companies Hospitals 52

Conversations in Drug Development Trends

DECEMBER 12, 2022

While the Genetic Information Nondiscrimination Act (GINA) prohibits discrimination by health insurance companies and employers based on a genetic test result, GINA does not apply to life, long-term care, or disability insurance. Once a sample is received at Invitae for a panel test, what happens next?

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

The Pharma Data

NOVEMBER 16, 2020

When taken on its own, the polypill reduced by about 20% the risk of heart attack, stroke, procedures to reopen clogged arteries and other heart disease, the researchers reported. The polypill combined with daily low-dose aspirin was even more effective, reducing heart health problems by up to 40%, the findings showed. About 4.1%

Health Insurance Companies 52

Health Insurance Companies Doctors Medical Schools Pharma Companies 52

The Pharma Data

NOVEMBER 10, 2020

Whatever the court finally decides is likely to have enormous ramifications, said Dr. Renuka Tipirneni, a health policy researcher and member of the University of Michigan’s Institute for Healthcare Policy and Innovation.

Health Insurance Companies 52

Health Insurance Companies Research Drugs 52